Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?
Saved in:
| Main Authors: | Yu Jun Wong, George Boon-Bee Goh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer – Medknow Publications
2025-04-01
|
| Series: | Singapore Medical Journal |
| Online Access: | https://journals.lww.com/10.4103/singaporemedj.SMJ-2025-051 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01) -
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01) -
Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology
by: Е. L. Nasonov, et al.
Published: (2024-04-01) -
Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
by: Xianhua Mao, et al.
Published: (2025-07-01)